SEARCH

SEARCH BY CITATION

References

  • 1
    Von Boehmer H. Selection of the T-cell repertoire: receptor-controlled checkpoints in T-cell development. Adv Immunol 2004; 84: 20138.
  • 2
    Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996; 381: 7518.
  • 3
    Vinuesa CG, Tangye SG, Moser B, Mackay CR. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005; 5: 85365.
  • 4
    Sinigaglia F, Hammer J. Defining rules for peptide-MHC class II interaction. Curr Opin Immunol 1994; 6: 526.
  • 5
    Wucherpfennig KW. The structural interactions between T cell receptors and MHC-peptide complexes place physical limits on self-nonself discrimination. Curr Top Microbiol Immunol 2005; 296: 1937.
  • 6
    Suri A, Lovitch SB, Unanue ER. The wide diversity and complexity of peptides bound to class II MHC molecules. Curr Opin Immunol 2006; 18: 707.
  • 7
    Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 24552.
  • 8
    Jones EY, Fugger L, Strominger JL, Siebold C. MHC class II proteins and disease: a structural perspective. Nat Rev Immunol 2006; 6: 27182.
  • 9
    Schueler-Furman O, Altubia Y, Margalit H. Examination of possible structural constraints of MHC-binding peptides by assessment of their native structure within their source proteins. Proteins 2001; 45: 4754.
  • 10
    Lovitch SB, Pu Z, Unanue ER. Amino-terminal flanking residues determine the conformation of a peptide-class II MHC complex. J Immunol 2006; 176: 295868.
  • 11
    Pu Z, Lovitch SB, Bikoff EK, Unanue ER. T cells distinguish MHC-peptide complexes formed in separate vesicles and edited by H2-DM. Immunity 2004; 20: 46776.
  • 12
    Gregersen JW, Holmes S, Fugger L. Humanized animal models for autoimmune diseases. Tissue Antigens 2004; 63: 38394.
  • 13
    Friese MA, Jensen LT, Willcox N, Fugger L. Humanized mouse models for organ-specific autoimmune diseases. Curr Opin Immunol 2006; 18: 7049.
  • 14
    Nishimura Y, Iwanaga T, Inamitsu T, Yanagawa Y, Yasunami M, Kimura A, Hirokawa K, Sasazuki T. Expression of the human MHC, HLA-DQW6 genes alters the immune response in C57BL/6 mice. J Immunol 1990; 145: 35360.
  • 15
    Madsen L, Labrecque N, Engberg J, Dierich A, Svejgaard A, Benoist C, Mathis D, Fugger L. Mice lacking all conventional MHC class II genes. Proc Natl Acad Sci USA 1999; 96: 1033843.
  • 16
    Das P, Abraham R, David C. HLA transgenic mice as models of human autoimmune diseases. Rev Immunogenet 2000; 2: 10514.
  • 17
    Larche M, Wraith D. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005; 11(Suppl. 4): S6976.
  • 18
    Abraham RS, David CS. Identification of HLA-class-II-restricted epitopes of autoantigens in transgenic mice. Curr Opin Immunol 2000; 12: 1229.
  • 19
    Mangalam AK, Rajagopalan G, Taneja V, David CS. HLA class II transgenic mice mimic human inflammatory diseases. Adv Immunol 2008; 97: 65147.
  • 20
    Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 23842.
  • 21
    Hay CR, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC, Colvin BT, Hill FG, Preston FE, Peake IR. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997; 77: 2347.
  • 22
    Pavlova D, Delev D, Oldenburg J. Contribution of polymorphisms in the IL-10, TNF alpha, CTLA-4 genes and HLA class II molecules to the risk of inhibitor development: A case-control study on 260 patients with severe hemophilia A. 53rd Annual Meeting Society of Thrombosis and Haemostasis Research. Hämostaseologie 2009; 29: FC46.
  • 23
    Madsen LS, Andersson EC, Jansson L, Krogsgaard M, Andersen CB, Engberg J, Strominger JL, Svejgaard A, Hjorth JP, Holmdahl R, Wucherpfennig KW, Fugger L. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet 1999; 23: 3437.
  • 24
    Ellmerich S, Mycko M, Takacs K, Waldner H, Wahid FN, Boyton RJ, King RH, Smith PA, Amor S, Herlihy AH, Hewitt RE, Jutton M, Price DA, Hafler DA, Kuchroo VK, Altmann DM. High incidence of spontaneous disease in an HLA-DR15 and TCR transgenic multiple sclerosis model. J Immunol 2005; 174: 193846.
  • 25
    Yahata T, Ando K, Nakamura Y, Ueyama Y, Shimamura K, Tamaoki N, Kato S, Hotta T. Functional human T lymphocyte development from cord blood CD34+ cells in nonobese diabetic/shi-scid, IL-2 receptor gamma null mice. J Immunol 2002; 169: 2049.
  • 26
    Hiramatsu H, Nishikomori R, Heike T, Ito M, Kobayashi K, Katamura K, Nakahata T. Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model. Blood 2003; 102: 87380.
  • 27
    Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2Rgammanull mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174: 647789.
  • 28
    Ishikawa F, Yasikawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, Watanabe T, Akashi K, Shultz LD, Harada M. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor gamma chain null mice. Blood 2005; 106: 156573.
  • 29
    Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti JC, Lanzavecchia A, Manz MG. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004; 304: 1047.
  • 30
    Gimeno R, Weijer K, Voordouw A, Uittenbogaart CH, Legrand N, Alves NL, Wijnands E, Blom B, Spits H. Monitoring the effect of gene silencing by RNA interference in human CD34+ cells injected into newborn RAG−/− yc−/− mice: functional inactivation of p53 in developing T cells. Blood 2004; 104: 388693.
  • 31
    Reipert BM, Hausl C, Sasgary M, Schuster M, Ahmad RU, Baumgartner B, Ilas J, Bauer N, Ehrlich H, Schwarz HP. Humanized E17 hemophilic mice are a major breakthrough in the design of new preclinical models for developing factor VIII products with reduced Immunogenicity. 49th Annual Meeting of the American Association of Hematology. Blood 2007; 110: 782.
  • 32
    Astermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, Lefvert AK. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 373945.
  • 33
    Vandenbark AA, Rich C, Mooney J, Zamora A, Wang C, Huan J, Fugger L, Offner H, Jones R, Burrows GG. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35–55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice. J Immunol 2003; 171: 12733.
  • 34
    Woods A, Chen HY, Trumbauer ME, Sirotina A, Cummings R, Zaller DM. Human major histocompatibility complex class II-restricted T cell responses in transgenic mice. J Exp Med 1994; 180: 17381.
  • 35
    Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 11921.
  • 36
    Bi L, Sarkar R, Naas T, Lawler AM, Pain J, Shumaker SL, Bedian V, Kazazian HH Jr. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 344650.
  • 37
    Muchitsch EM, Turecek PL, Zimmermann K, Pichler L, Auer W, Richter G, Gritsch H, Schwarz HP. Phenotypic expression of murine hemophilia. Thromb Haemost 1999; 82: 13713.